{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:03:42Z","timestamp":1768482222627,"version":"3.49.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clgc.2022.08.005","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T02:17:31Z","timestamp":1661221051000},"page":"553-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2751-5915","authenticated-orcid":false,"given":"Zeynep B.","family":"Zengin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Verzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Kasturi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-080X","authenticated-orcid":false,"given":"Brian","family":"Rini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.08.005_bib0001","unstructured":"Kidney Cancer (Version 1.2022). National Comprehensive Cancer Network; 2021 299 Accessed September 7 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf"},{"key":"10.1016\/j.clgc.2022.08.005_bib0002","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.08.005_bib0003","series-title":"FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma","article-title":"Center for Drug Evaluation and Research","author":"Food","year":"2021"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2022.08.005_bib0004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.2021.39.6_suppl.278","article-title":"TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib","volume":"39","author":"Rini","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.clgc.2022.08.005_bib0005","article-title":"Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma","volume":"0","author":"Pal","year":"2020","journal-title":"European Urology"},{"key":"10.1016\/j.clgc.2022.08.005_bib0006","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/2160763X12447303","article-title":"Absorption, Metabolism, and Excretion of [(14) C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open-Label, Mass-Balance Study","volume":"1","author":"Cotreau","year":"2012","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.clgc.2022.08.005_bib0007","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6602584","article-title":"Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on\/7 days off in patients with advanced, refractory solid tumours","volume":"92","author":"Awada","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2022.08.005_bib0008","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/annonc\/mdi310","article-title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on\/7 days off in patients with advanced, refractory solid tumors","volume":"16","author":"Moore","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.08.005_bib0009","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.08.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101966","article-title":"Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs","volume":"84","author":"Fogli","year":"2020","journal-title":"Cancer Treatment Rev"},{"key":"10.1016\/j.clgc.2022.08.005_bib0011","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/02841860701765675","article-title":"Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis","volume":"47","author":"Chu","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2022.08.005_bib0012","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"PNAS"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:18Z","timestamp":1761564918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322001732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1558767322001732"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.08.005","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}